Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 290

1.

A Randomised Controlled Trial of Consent Procedures for the Use of Residual Tissues for Medical Research: Preferences of and Implications for Patients, Research and Clinical Practice.

Rebers S, Vermeulen E, Brandenburg AP, Stoof TJ, Zupan-Kajcovski B, Bos WJ, Jonker MJ, Bax CJ, van Driel WJ, Verwaal VJ, van den Brekel MW, Grutters JC, Tupker RA, Plusjé L, de Bree R, Schagen van Leeuwen JH, Vermeulen EG, de Leeuw RA, Brohet RM, Aaronson NK, Van Leeuwen FE, Schmidt MK.

PLoS One. 2016 Mar 30;11(3):e0152509. doi: 10.1371/journal.pone.0152509. eCollection 2016.

2.

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.

Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O, Rutgers EJ, Aleman BM, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1061-72. doi: 10.1016/j.ijrobp.2015.11.040. Epub 2015 Dec 14.

PMID:
27026313
3.

Participation rates of childhood cancer survivors to self-administered questionnaires: a systematic review.

Kilsdonk E, Wendel E, van Dulmen-den Broeder E, van Leeuwen FE, van den Berg MH, Jaspers MW.

Eur J Cancer Care (Engl). 2016 Feb 16. doi: 10.1111/ecc.12462. [Epub ahead of print]

PMID:
26880318
4.

Exceptions to the rule of informed consent for research with an intervention.

Rebers S, Aaronson NK, van Leeuwen FE, Schmidt MK.

BMC Med Ethics. 2016 Feb 6;17:9. doi: 10.1186/s12910-016-0092-6.

5.

Anthracyclines and Alkylating Agents: New Risk Factors for Breast Cancer in Childhood Cancer Survivors?

van Leeuwen FE, Ronckers CM.

J Clin Oncol. 2016 Mar 20;34(9):891-4. doi: 10.1200/JCO.2015.65.0465. Epub 2016 Feb 1. No abstract available.

PMID:
26834056
6.

Risk of subsequent gastrointestinal cancer among childhood cancer survivors: A systematic review.

Teepen JC, de Vroom SL, van Leeuwen FE, Tissing WJ, Kremer LC, Ronckers CM.

Cancer Treat Rev. 2016 Feb;43:92-103. doi: 10.1016/j.ctrv.2015.12.002. Epub 2015 Dec 17. Review.

PMID:
26827697
7.

Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study.

Paalman CH, van Leeuwen FE, Aaronson NK, de Boer AG, van de Poll-Franse L, Oldenburg HS, Schaapveld M.

Br J Cancer. 2016 Jan 12;114(1):81-7. doi: 10.1038/bjc.2015.431.

8.

Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.

van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK.

J Clin Oncol. 2016 Feb 10;34(5):409-18. doi: 10.1200/JCO.2015.62.3942. Epub 2015 Dec 23.

PMID:
26700119
9.

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE.

N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.

10.

Risk of Colorectal Cancer After Ovarian Stimulation for In Vitro Fertilization.

Spaan M, van den Belt-Dusebout AW, Burger CW, van Leeuwen FE; OMEGA-project group.

Clin Gastroenterol Hepatol. 2016 May;14(5):729-737.e5. doi: 10.1016/j.cgh.2015.12.018. Epub 2015 Dec 12.

PMID:
26687912
11.

[The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment].

Dekker N, van 't Veer MB, Aleman BM, van Leeuwen FE, Raemaekers JM.

Ned Tijdschr Geneeskd. 2015;159:A9269. Dutch.

PMID:
26577382
12.

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.

van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2016 Jan 20;34(3):235-43. doi: 10.1200/JCO.2015.63.4444. Epub 2015 Nov 16.

PMID:
26573075
13.

Current knowledge and future research directions in treatment-related second primary malignancies.

Morton LM, Swerdlow AJ, Schaapveld M, Ramadan S, Hodgson DC, Radford J, van Leeuwen FE.

EJC Suppl. 2014 Jun;12(1):5-17. doi: 10.1016/j.ejcsup.2014.05.001. Epub 2014 May 29.

14.

European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk.

Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, Romieu I, Segnan N, Wardle J, Wiseman M, Belardelli F, Bettcher D, Cavalli F, Galea G, Lenoir G, Martin-Moreno JM, Nicula FA, Olsen JH, Patnick J, Primic-Zakelj M, Puska P, van Leeuwen FE, Wiestler O, Zatonski W; Working Groups of Scientific Experts.

Cancer Epidemiol. 2015 Dec;39 Suppl 1:S1-10. doi: 10.1016/j.canep.2015.05.009. Epub 2015 Jul 9.

15.

Studying Hospitalizations and Mortality in the Netherlands: Feasible and Valid Using Two-Step Medical Record Linkage with Nationwide Registers.

Sieswerda E, Font-Gonzalez A, Dijkgraaf MG, Geskus RB, Heinen RC, van der Pal HJ, van Leeuwen FE, Caron HN, Kremer LC, Reitsma JB.

PLoS One. 2015 Jul 6;10(7):e0132444. doi: 10.1371/journal.pone.0132444. eCollection 2015.

16.

The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors.

van Gemert WA, Lanting CI, Goldbohm RA, van den Brandt PA, Grooters HG, Kampman E, Kiemeney LA, van Leeuwen FE, Monninkhof EM, de Vries E, Peeters PH, Elias SG.

Breast Cancer Res Treat. 2015 Jul;152(1):155-62. doi: 10.1007/s10549-015-3447-7. Epub 2015 Jun 5.

17.

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS; Breast Cancer Family Registry, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Conejero RA, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE, Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F; GEMO Study Collaborators, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon YJ, Carter J, Van Le L, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomäki K, Jager A, van den Ouweland AM, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FB, Meijers-Heijboer HE; HEBON, Oosterwijk JC, van Roozendaal KE, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teulé A, Lazaro C, Blanco I, Del Valle J, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, Foulkes W, Olswold C, Lindor NM, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Toland AE, Pedersen IS, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade OI, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG.

Breast Cancer Res. 2015 Apr 25;17:61. doi: 10.1186/s13058-015-0567-2.

18.

Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE.

JAMA Intern Med. 2015 Jun;175(6):1007-17. doi: 10.1001/jamainternmed.2015.1180.

PMID:
25915855
19.

Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation X-rays.

van Nimwegen FA, Cutter DJ, Schaapveld M, Rutten A, Kooijman K, Krol AD, Janus CP, Darby SC, van Leeuwen FE, Aleman BM.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):153-60. doi: 10.1016/j.ijrobp.2015.02.019.

PMID:
25863762
20.

[Hypofractionated adjuvant radiotherapy for breast cancer: no signs of increased risk of cardiotoxicity].

Aleman BM, van Leeuwen FE.

Ned Tijdschr Geneeskd. 2015;159:A8856. Dutch.

PMID:
25827153
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk